Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.37.2649PMID 22547589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

  2011cited by this paper
• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  2010cited by this paper
• Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

  2010cited by this paper
• Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

  2009cited by this paper
• Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

  2009cited by this paper
• Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

  2008cited by this paper
• CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

  2008cited by this paper
• Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab

  2008cited by this paper
• Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

  2007cited by this paper
• Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo

  2007cited by this paper
• HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Clinical course of patients with relapsed multiple myeloma.

  2004cited by this paper
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

  2001cited by this paper

• Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma

  2025cites this paper
• Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes

  2025cites this paper
• SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma

  2025cites this paper
• A review: Mechanisms and molecular pathways of signaling lymphocytic activation molecule family 3 (SLAMF3) in immune modulation and therapeutic prospects.

  2024cites this paper
• A Journey Through the Golden Era of Myeloma Treatment: From Bench to Bedside.

  2024cites this paper
• Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

  2024cites this paper
• Monoclonal Gammopathy of Renal Significance: multidisciplinary approach to diagnosis and treatment.

  2023cites this paper
• Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy

  2023cites this paper
• Immune checkpoint inhibitors for multiple myeloma immunotherapy

  2023cites this paper
• SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy

  2023cites this paper
• Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.

  2023cites this paper
• Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

  2022cites this paper
• Randomized Controlled Trials versus Single Cohort Studies in Relapse Refractory Multiple Myeloma

  2021cites this paper
• The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance

  2021cites this paper
• Targeted Therapies for Multiple Myeloma

  2021cites this paper
• Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients

  2021cites this paper
• A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma

  2021cites this paper
• Elotuzumab

  2021cites this paper
• Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs

  2021cites this paper
• Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

  2021cites this paper
• Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

  2021influential citation
• Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects

  2021cites this paper
• Venous thromboembolism risk with contemporary lenalidomide‐based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta‐analysis

  2020cites this paper
• Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients

  2020cites this paper
• Current Development of Monoclonal Antibodies in Cancer Therapy.

  2020cites this paper
• NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias

  2020cites this paper
• Monoclonal antibodies: A prospective and retrospective view.

  2020cites this paper
• The clinical potential of gene editing as a tool to engineer cell-based therapeutics

  2020cites this paper
• Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

  2020influential citation
• Natural Killer Cells: Tumor Surveillance and Signaling

  2020cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report.

  2020cites this paper
• Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

  2020cites this paper
• Potential of NK cells in multiple Myeloma therapy

  2019cites this paper
• Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?

  2019cites this paper
• [PET/CT with 18F-fluorodeoxyglucose and 11C-methionine after autologous stem cell transplantation in multiple myeloma patients].

  2019cites this paper
• SLAMF6 in health and disease: Implications for therapeutic targeting.

  2019cites this paper
• Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

  2019cites this paper
• Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.

  2019cites this paper
• Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

  2019cites this paper
• Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma

  2019cites this paper
• OTT_A_174640 5813..5822

  2019cites this paper
• Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma

  2019cites this paper
• Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

  2019cites this paper
• Treatment of relapsed multiple myeloma: Evidence-based recommendations.

  2019cites this paper
• Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma

  2019cites this paper
• Natural killer cells, multiple myeloma, and daratumumab : a love-hate relationship

  2019cites this paper
• Novel targets for the treatment of relapsing multiple myeloma

  2019cites this paper
• The therapeutic role of natural killer cells in multiple myeloma

  2019cites this paper
• Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

  2019cites this paper
• Immunotherapy in Multiple Myeloma

  2019cites this paper
• New Drugs in Multiple Myeloma.

  2019cites this paper
• Novel Agents in Multiple Myeloma.

  2019cites this paper
• Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective

  2019cites this paper
• Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma

  2018cites this paper
• The bone-marrow niche in MDS and MGUS: implications for AML and MM

  2018cites this paper
• The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma

  2018cites this paper
• Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling

  2018cites this paper
• Translating the anti-myeloma activity of Natural Killer cells into clinical application.

  2018cites this paper
• Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

  2018cites this paper
• Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets

  2018cites this paper
• CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma

  2018cites this paper
• A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.

  2018cites this paper
• Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies

  2018cites this paper
• How I treat the young patient with multiple myeloma.

  2018cites this paper
• Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy

  2018cites this paper
• Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

  2018cites this paper
• Update on the role of lenalidomide in patients with multiple myeloma

  2018cites this paper
• Disease Milestones through Bibliometric Analysis of the Top 100 Cited Articles in Multiple Myeloma

  2018cites this paper
• Current use of monoclonal antibodies in the treatment of multiple myeloma

  2018cites this paper
• The Clinical Pharmacology of Elotuzumab

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).

  2018cites this paper
• Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities

  2018cites this paper
• Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

  2018cites this paper
• New Methods in Treatment of Renal Failure in Patients with Multiple Myeloma : A Review with Immunological Approach

  2017cites this paper
• Advances in immunotherapy in multiple myeloma

  2017cites this paper
• Academic, Foundation, and Industry Collaboration in Finding New Therapies

  2017cites this paper
• The role of SLAMF7 in multiple myeloma: impact on therapy

  2017influential citation
• Therapy for Relapsed Multiple Myeloma: GUIDELINES FROM THE MAYO STRATIFICATION FOR MYELOMA AND RISK‐ADAPTED THERAPY

  2017cites this paper
• Emerging drugs and combinations to treat multiple myeloma

  2017cites this paper
• Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.

  2017cites this paper
• Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy

  2017cites this paper
• Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.

  2017cites this paper
• Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs

  2017cites this paper
• Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication

  2017cites this paper
• Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab

  2017cites this paper
• Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma

  2017influential citation
• Role of Passive Diffusion, Transporters, and Membrane Trafficking‐Mediated Processes in Cellular Drug Transport

  2017cites this paper
• Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

  2017cites this paper
• An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab

  2017cites this paper
• Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling

  2017cites this paper
• Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

  2017cites this paper
• Novel anti-myeloma immunotherapies targeting the SLAM family of receptors

  2017cites this paper
• Immunologic approaches for the treatment of multiple myeloma.

  2017cites this paper
• The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

  2017cites this paper
• Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study

  2017cites this paper
• Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

  2017cites this paper
• A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma

  2017cites this paper
• Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma

  2017cites this paper
• Monoclonal antibody therapy in multiple myeloma

  2017cites this paper